Partnering with Boehringer Ingelheim: BIO International 2024
Learn about innovation and partnering with Boehringer Ingelheim human pharma, animal health and biopharma contract manufacturing at BIO International 2024
Search
Dr. Hsing-Jung Chen-Engerer
Dr. Hsing-Jung Chen-Engerer of Research & Development speaks about his fulfilling career with Boehringer Ingelheim.
Patricia Rangel
Patricia Rangel of Corporate Strategy & Consulting describes Boehringer Ingelheim as a family company that operates with the highest integrity standards.
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Alex Breiner
Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.
Liliana Montano
Liliana Montano works as a scientist within the Global Innovation and Alliance Management and talks about her journey at Boehringer Ingelheim.
Driving Innovation through Diversity & Inclusion
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Thorsten von Goessel
Thorsten von Goessel of Engineering & Facilities, describes Boehringer Ingelheim as family business with long-term perspective and wonderful leadership team.
agustina-rojo
Agustina Rojo, System Analyst in Buenos Aires, Argentina explains the many career opportunities Boehringer Ingelheim provides its employees.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
Ukraine Help: We fly, we bike, we accommodate
The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
founding-member-of-QUTAC
Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
world rabies day 2019
world rabies day 2019
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Circular economy
Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.